KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other

Matthew K. Tollefson, R. Houston Thompson, Yuri Sheinin, Christine M. Lohse, John C. Cheville, Bradley C. Leibovich, Eugene D. Kwon

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

BACKGROUND. Ki-67 is a cell proliferation protein associated with aggressive clear cell renal cell carcinoma (ccRCC). A recent report suggests that Ki-67 may represent a surrogate marker for coagulative tumor necrosis. Thus, the goal was to directly test whether Ki-67 and necrosis convey similar or distinct information for the prognostic assessment of ccRCC. METHODS. Tumor specimens from 741 consecutively treated patients who underwent surgery for ccRCC between 1990 and 1999 were evaluated. Tumor specimens were assessed for various clinicopathologic features, including levels of tumor cell Ki-67 expression. Associations of these features with death from RCC were evaluated using Cox proportional hazards regression models. RESULTS. At last follow-up, 396 patients had died, including 238 who died from ccRCC at a median of 2.1 years after surgery. Although tumor cell Ki-67 expression and coagulative tumor necrosis were highly correlated, the prognostic information conveyed by these 2 markers failed to overlap. For the subset of patients with necrotic tumors, high levels of Ki-67 more than doubled the risk of death from RCC (risk ratio, 2.18; 95% confidence interval [CI], 1.52-3.11; P < .001). For patients with tumors lacking necrosis, high levels of Ki-67 expression were similarly correlated with an increased risk of death from RCC (risk ratio, 2.50; 95% CI, 1.66-3.77; P< .001). CONCLUSIONS. Prognostic information conveyed by Ki-67 and coagulative tumor necrosis are not interchangeable. Thus, Ki-67 and coagulative tumor necrosis should not be treated as surrogates for one another and both of these features should be evaluated when generating outcome predictions for patients with ccRCC.

Original languageEnglish (US)
Pages (from-to)783-790
Number of pages8
JournalCancer
Volume110
Issue number4
DOIs
StatePublished - Aug 15 2007

Fingerprint

Renal Cell Carcinoma
Necrosis
Neoplasms
Odds Ratio
Confidence Intervals
Proportional Hazards Models
Biomarkers
Cell Proliferation

Keywords

  • Disease recurrence
  • Molecular markers
  • Renal cell carcinoma
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tollefson, M. K., Thompson, R. H., Sheinin, Y., Lohse, C. M., Cheville, J. C., Leibovich, B. C., & Kwon, E. D. (2007). KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer, 110(4), 783-790. https://doi.org/10.1002/cncr.22840

KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. / Tollefson, Matthew K.; Thompson, R. Houston; Sheinin, Yuri; Lohse, Christine M.; Cheville, John C.; Leibovich, Bradley C.; Kwon, Eugene D.

In: Cancer, Vol. 110, No. 4, 15.08.2007, p. 783-790.

Research output: Contribution to journalArticle

Tollefson, Matthew K. ; Thompson, R. Houston ; Sheinin, Yuri ; Lohse, Christine M. ; Cheville, John C. ; Leibovich, Bradley C. ; Kwon, Eugene D. / KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. In: Cancer. 2007 ; Vol. 110, No. 4. pp. 783-790.
@article{7ddeb6c39eb64657936132695f99ae04,
title = "KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other",
abstract = "BACKGROUND. Ki-67 is a cell proliferation protein associated with aggressive clear cell renal cell carcinoma (ccRCC). A recent report suggests that Ki-67 may represent a surrogate marker for coagulative tumor necrosis. Thus, the goal was to directly test whether Ki-67 and necrosis convey similar or distinct information for the prognostic assessment of ccRCC. METHODS. Tumor specimens from 741 consecutively treated patients who underwent surgery for ccRCC between 1990 and 1999 were evaluated. Tumor specimens were assessed for various clinicopathologic features, including levels of tumor cell Ki-67 expression. Associations of these features with death from RCC were evaluated using Cox proportional hazards regression models. RESULTS. At last follow-up, 396 patients had died, including 238 who died from ccRCC at a median of 2.1 years after surgery. Although tumor cell Ki-67 expression and coagulative tumor necrosis were highly correlated, the prognostic information conveyed by these 2 markers failed to overlap. For the subset of patients with necrotic tumors, high levels of Ki-67 more than doubled the risk of death from RCC (risk ratio, 2.18; 95{\%} confidence interval [CI], 1.52-3.11; P < .001). For patients with tumors lacking necrosis, high levels of Ki-67 expression were similarly correlated with an increased risk of death from RCC (risk ratio, 2.50; 95{\%} CI, 1.66-3.77; P< .001). CONCLUSIONS. Prognostic information conveyed by Ki-67 and coagulative tumor necrosis are not interchangeable. Thus, Ki-67 and coagulative tumor necrosis should not be treated as surrogates for one another and both of these features should be evaluated when generating outcome predictions for patients with ccRCC.",
keywords = "Disease recurrence, Molecular markers, Renal cell carcinoma, Survival",
author = "Tollefson, {Matthew K.} and Thompson, {R. Houston} and Yuri Sheinin and Lohse, {Christine M.} and Cheville, {John C.} and Leibovich, {Bradley C.} and Kwon, {Eugene D.}",
year = "2007",
month = "8",
day = "15",
doi = "10.1002/cncr.22840",
language = "English (US)",
volume = "110",
pages = "783--790",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other

AU - Tollefson, Matthew K.

AU - Thompson, R. Houston

AU - Sheinin, Yuri

AU - Lohse, Christine M.

AU - Cheville, John C.

AU - Leibovich, Bradley C.

AU - Kwon, Eugene D.

PY - 2007/8/15

Y1 - 2007/8/15

N2 - BACKGROUND. Ki-67 is a cell proliferation protein associated with aggressive clear cell renal cell carcinoma (ccRCC). A recent report suggests that Ki-67 may represent a surrogate marker for coagulative tumor necrosis. Thus, the goal was to directly test whether Ki-67 and necrosis convey similar or distinct information for the prognostic assessment of ccRCC. METHODS. Tumor specimens from 741 consecutively treated patients who underwent surgery for ccRCC between 1990 and 1999 were evaluated. Tumor specimens were assessed for various clinicopathologic features, including levels of tumor cell Ki-67 expression. Associations of these features with death from RCC were evaluated using Cox proportional hazards regression models. RESULTS. At last follow-up, 396 patients had died, including 238 who died from ccRCC at a median of 2.1 years after surgery. Although tumor cell Ki-67 expression and coagulative tumor necrosis were highly correlated, the prognostic information conveyed by these 2 markers failed to overlap. For the subset of patients with necrotic tumors, high levels of Ki-67 more than doubled the risk of death from RCC (risk ratio, 2.18; 95% confidence interval [CI], 1.52-3.11; P < .001). For patients with tumors lacking necrosis, high levels of Ki-67 expression were similarly correlated with an increased risk of death from RCC (risk ratio, 2.50; 95% CI, 1.66-3.77; P< .001). CONCLUSIONS. Prognostic information conveyed by Ki-67 and coagulative tumor necrosis are not interchangeable. Thus, Ki-67 and coagulative tumor necrosis should not be treated as surrogates for one another and both of these features should be evaluated when generating outcome predictions for patients with ccRCC.

AB - BACKGROUND. Ki-67 is a cell proliferation protein associated with aggressive clear cell renal cell carcinoma (ccRCC). A recent report suggests that Ki-67 may represent a surrogate marker for coagulative tumor necrosis. Thus, the goal was to directly test whether Ki-67 and necrosis convey similar or distinct information for the prognostic assessment of ccRCC. METHODS. Tumor specimens from 741 consecutively treated patients who underwent surgery for ccRCC between 1990 and 1999 were evaluated. Tumor specimens were assessed for various clinicopathologic features, including levels of tumor cell Ki-67 expression. Associations of these features with death from RCC were evaluated using Cox proportional hazards regression models. RESULTS. At last follow-up, 396 patients had died, including 238 who died from ccRCC at a median of 2.1 years after surgery. Although tumor cell Ki-67 expression and coagulative tumor necrosis were highly correlated, the prognostic information conveyed by these 2 markers failed to overlap. For the subset of patients with necrotic tumors, high levels of Ki-67 more than doubled the risk of death from RCC (risk ratio, 2.18; 95% confidence interval [CI], 1.52-3.11; P < .001). For patients with tumors lacking necrosis, high levels of Ki-67 expression were similarly correlated with an increased risk of death from RCC (risk ratio, 2.50; 95% CI, 1.66-3.77; P< .001). CONCLUSIONS. Prognostic information conveyed by Ki-67 and coagulative tumor necrosis are not interchangeable. Thus, Ki-67 and coagulative tumor necrosis should not be treated as surrogates for one another and both of these features should be evaluated when generating outcome predictions for patients with ccRCC.

KW - Disease recurrence

KW - Molecular markers

KW - Renal cell carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34547893437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547893437&partnerID=8YFLogxK

U2 - 10.1002/cncr.22840

DO - 10.1002/cncr.22840

M3 - Article

VL - 110

SP - 783

EP - 790

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -